Immune response elicited in HBV-transgenic mice by cytoplasmic transduction peptide-HBcAg18-27-Tapasin adjuvanted with CpG ODN

doi:10.12092/j.issn.1009-2501.2018.03.005

Abstract

Abstract:

AIM: To investigate the effects of fusion protein of cytoplasmic transduction peptide (CTP) -HBcAg18-27-Tapasin adjuvanted with CpG ODN on immune response and anti-viral response in HBV transgenic mice. METHODS: HBV-transgenic mice were randomly divided into 5 groups: experimental group: CTP-HBcAg18-27-Tapasin+CpG ODN, control group: CpG ODN, IFN-α and CTP-HBcAg18-27-Tapasin, vehicle group: normal saline. Serum samples were collected at various times before and after immunization. Intracellular cytokine in T lymphocytes was analyzed by flow cytometry, and the levels of IL-2 and IFN-γ secreted by T lymphocytes were detected by ELISA. The expression of HBsAg in liver sections was detected by immunohistochemistry. Sera levels of HBV DNA and HBsAg were examined by qRT-PCR and automatic enzyme-linked immunosorbent assay, respectively. RESULTS:An increased percentage of IFN-γ+CD8+ T cells was detected in CTP-HBcAg18-27-Tapasin+CpG ODN group and predominantly Th1 cellular immune response. In addition, the expression levels of serum HBsAg and HBV DNA were significantly inhibited, along with evident down-regulation of HBsAg in liver samples than CTP-HBcAg18-27-Tapasin alone group. CONCLUSION: CpG ODN acts as adjuvant could enhance anti-virus immune responses in HBV transgenic mice immunized with fusion protein CTP-HBcAg18-27-Tapasin.

Key words: CTP-HBcAg18-27-Tapasin, antiviral immune response, adjuvant

CLC Number:

R965.2

WU Shanshan, TANG Yuyan, CHEN Xiaohua, ZHANG Yi, WANG Jieling, TANG Zhenghao, ZANG Guoqing, YU Yongsheng . Immune response elicited in HBV-transgenic mice by cytoplasmic transduction peptide-HBcAg18-27-Tapasin adjuvanted with CpG ODN[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 271-276.

References

［1］Christoph HS, Markus C. The role of HBsAg levels in the currentmanagement of chronic HBV infection［J］. Ann Gastroenterol, 2014, 27(2): 105-112.
［2］Liu J, Kosinska A, Lu M, et al. New therapeutic vaccination strategies for the treatment of chronic hepatitis B［J］. Virologica Sinica, 2014, 29(1):10-16.
［3］Sandhu P, Haque M, Humphries-Bickley T, et al. Hepatitis B virus immunopathology, model systems, and current therapies［J］. Front Immunol, 2017, 8, 436.
［4］Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro［J］. Blood, 2004, 103(6):2162-2169.
［5］Fisette O, Wingbermühle S, Tampé R, et al. Molecular mechanism of peptide editing in the tapasin-MHC I complex［J］. Sci Rep, 2016, 6, 19085.
［6］刘红红, 陈小华, 周丽芹, 等. CTP-HBcAg18-27-Tapasin融合表达载体的构建及其表达和纯化［J］. 胃肠病学和肝病学杂志, 2013,22（7）：684-687.
［7］Schuch A, Hoh A, Thimme R. The Role of Natural Killer Cells and CD8+ T Cells in Hepatitis B Virus Infection［J］. Front Immunol,2014, 5: 258.
［8］Jang-June P, David KW, Abdus SW, et al. HBV-specific and global T-cell dysfunction in chronic hepatitis B［J］. Gastroenterology, 2016, 150(3): 684-695.
［9］Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection［J］. J Immunol, 1990, 145(10):3442-3449.
［10］Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and diseasepathogenesis during acute hepatitis B virus infection［J］. J Virol, 2003, 77(1) :68-76.
［11］Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus［J］. Antiviral Res, 2012, 96(1): 59-64.
［12］Dammermann W, Dornbrack J, Brker K, et al. CpG oligonucleotides increase HBV-specific cytokine responses in whole blood and enhance cytokine release assay sensitivity［J］. J Virol Methods, 2017, 248:195-201.
［13］Balmasova IP, Yushchuk ND, Mynbaev OA, et al. Immunopathogenesis of chronic hepatitis B［J］. World J Gastroenterol, 2014, 20(39):14156-14171.
［14］林良沫，黄春新，韩方璇.1例肝移植患者术后免疫抑制剂和抗HBV药物的药学监护［J］. 中国药物应用与监测，2016，13(6):345-348.
［15］唐余燕, 陈小华, 汤正好, 等. 胞质转导肽-HBcAg18-27-Tapasin诱导C57BL/6小鼠T淋巴细胞分泌Th1型细胞因子及HBV特异性CTL的表达［J］. 细胞与分子免疫学杂志, 2013, 29 (3): 229-232.

[1]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[2]	LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie. Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
[3]	CHENG Run, DING Wenxi, YAN Shangxue, WEI Wei. Human umbilical cord-derived mesenchymal stem cells alleviate adjuvant arthritis by regulating macrophage in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1335-1340.
[4]	CAO Ting, LI Nana, CAI Hualin. Progress in neurosteroids related to the pathogenesis and treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 709-714.
[5]	LUO Yong, LI Qi, HUA Tebo. Effects of neo-adjuvant chemotherapy combined with modified radical mastectomy on clinical effect and tumor markers in patients with breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 104-109.
[6]	JIANG Sanya, SHAN Yabing, CHEN Wenbin. Comparison study of modified FOLFOX6 combined with durative transfusion of endostatin as neoadjuvant treatment vs. treatment without endostatin for locally advanced rectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 674-679.
[7]	YANG Zuqin, WANG Ying, CHEN Yingying. Study on the adjuvant therapy of low birth weight infants with sepsis by IgM-rich immunoglobulin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 174-178.
[8]	HU Min, SHAO Ming-jun, HE Yun-qin, ZHOU Meng-xiong. Clinical observation on effect of neoadjuvant chemotherapy with gemcitabine hydrochloride in patients with cervical cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 454-457.
[9]	ZENG Yang, MA Ji-xiong, BAO Min, CHEN Hai-juan, ZHANG Guo-yan, ZHANG Hong-quan. Therapeutic effects of total glucosides of Tibetan Herb Myricaria paniculata auct non Linn. Desv on adjuvant arthritis in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1321-1325.
[10]	ZHANG Teng-yue, CHEN Fei-hu, WANG Nian, YUAN Feng-lai, HU Wei, WU Fanrong. Inhibitions of articular cartilage cells apoptosis in rats with adjuvant arthritis by Amiloride, a blocker of acid-sensing ion channels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 41-46.
[11]	CHEN Fei-hu, YUAN Feng-lai, LI Xia, WU Fan-rong, HUANG Xue-ying, HU Wei, HENG Juan, LI Jun. Effects of several anti-rheumatoid arthritis drugs on expression of acidsensitive ion channels in articular chondrocytes in rats with adjuvant arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(2): 131-137.
[12]	HUANG Xue-ying, CHEN Fei-hu, LIU Yong-jing, ZHANG Xiao-ming, YUAN Feng-lai. Effects of recombinant human endostatin on the expression of apoptosisrelated genes in synovial tissue in rats with adjuvant arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1359-1363.
[13]	XIA Li-juan, CHEN Fei-hu, HUANG Xue-ying, LIU Yong-jing, LI Jun. Effect of recombinant human endostatin on expression of vascular endothelial cell growth factor in adjuvant arthritis synovium tissue [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 760-763.
[14]	BING Fei-hong, ZHANG Guo-bin, DENG Cheng-zhi, SU Yan-qi. Prophylactic and therapeutic effects of Mugua Pill on adjuvant-induced arthritis in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(5): 590-592.
[15]	LU Yan-Xu, CHEN Min-Zhu, LU Jing-Tao. Combined therapeutic effects of recombinant human IL-10 with soluble chicken type Ⅱ collagen on experimental arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 426-429.